Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 185 entries
Sorted by: Best Match Show Resources per page
Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism.

Clinical and experimental gastroenterology

de Campos Mazo DF, de Vasconcelos GB, Pereira MA, de Mello ES, Bacchella T, Carrilho FJ, Cançado EL.
PMID: 23550044
Clin Exp Gastroenterol. 2013;6:9-17. doi: 10.2147/CEG.S39358. Epub 2013 Feb 19.

Liver dysfunction in patients with hyperthyroidism includes abnormalities associated with the effects of thyroid hormone excess, those secondary to drug-induced liver injury, and changes resulting from concomitant liver disease. Our goal was to describe clinical, biochemical, and histopathological patterns...

Cite
de Campos Mazo DF, de Vasconcelos GB, Pereira MA, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol. 2013;6:9-17doi: 10.2147/CEG.S39358.
de Campos Mazo, D. F., de Vasconcelos, G. B., Pereira, M. A., de Mello, E. S., Bacchella, T., Carrilho, F. J., & Cançado, E. L. (2013). Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clinical and experimental gastroenterology, 69-17. https://doi.org/10.2147/CEG.S39358
de Campos Mazo, Daniel Ferraz, et al. "Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism." Clinical and experimental gastroenterology vol. 6 (2013): 9-17. doi: https://doi.org/10.2147/CEG.S39358
de Campos Mazo DF, de Vasconcelos GB, Pereira MA, de Mello ES, Bacchella T, Carrilho FJ, Cançado EL. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol. 2013;6:9-17. doi: 10.2147/CEG.S39358. Epub 2013 Feb 19. PMID: 23550044; PMCID: PMC3579408.
Copy Download .nbib Format: NLM
Controlled Veiling of Silver Nanocubes with Graphene Oxide for Improved Surface-Enhanced Raman Scattering Detection.

ACS applied materials & interfaces

Banchelli M, Tiribilli B, de Angelis M, Pini R, Caminati G, Matteini P.
PMID: 26751095
ACS Appl Mater Interfaces. 2016 Feb 03;8(4):2628-34. doi: 10.1021/acsami.5b10438. Epub 2016 Jan 21.

Hybrid graphene oxide (GO)/metal nanocomposites have been recently proposed as novel surface-enhanced Raman scattering (SERS) substrates. Despite an increasing interest in these systems, standardization in their fabrication process is still lacking but urgently required to support their use for...

Cite
Banchelli M, Tiribilli B, de Angelis M, et al. Controlled Veiling of Silver Nanocubes with Graphene Oxide for Improved Surface-Enhanced Raman Scattering Detection. ACS Appl Mater Interfaces. 2016;8(4):2628-34doi: 10.1021/acsami.5b10438.
Banchelli, M., Tiribilli, B., de Angelis, M., Pini, R., Caminati, G., & Matteini, P. (2016). Controlled Veiling of Silver Nanocubes with Graphene Oxide for Improved Surface-Enhanced Raman Scattering Detection. ACS applied materials & interfaces, 8(4), 2628-34. https://doi.org/10.1021/acsami.5b10438
Banchelli, Martina, et al. "Controlled Veiling of Silver Nanocubes with Graphene Oxide for Improved Surface-Enhanced Raman Scattering Detection." ACS applied materials & interfaces vol. 8,4 (2016): 2628-34. doi: https://doi.org/10.1021/acsami.5b10438
Banchelli M, Tiribilli B, de Angelis M, Pini R, Caminati G, Matteini P. Controlled Veiling of Silver Nanocubes with Graphene Oxide for Improved Surface-Enhanced Raman Scattering Detection. ACS Appl Mater Interfaces. 2016 Feb 03;8(4):2628-34. doi: 10.1021/acsami.5b10438. Epub 2016 Jan 21. PMID: 26751095.
Copy Download .nbib Format: NLM
Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Molecular therapy. Methods & clinical development

Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C.
PMID: 28344996
Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17.

Lentiviral vectors (LVs) are a highly valuable tool for gene transfer currently exploited in basic, applied, and clinical studies. Their optimization is therefore very important for the field of vectorology and gene therapy. A key molecule for LV function...

Cite
Zucchelli E, Pema M, Stornaiuolo A, et al. Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Mol Ther Methods Clin Dev. 2017;4:102-114doi: 10.1016/j.omtm.2017.01.002.
Zucchelli, E., Pema, M., Stornaiuolo, A., Piovan, C., Scavullo, C., Giuliani, E., Bossi, S., Corna, S., Asperti, C., Bordignon, C., Rizzardi, G. P., & Bovolenta, C. (2017). Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Molecular therapy. Methods & clinical development, 4102-114. https://doi.org/10.1016/j.omtm.2017.01.002
Zucchelli, Eleonora, et al. "Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein." Molecular therapy. Methods & clinical development vol. 4 (2017): 102-114. doi: https://doi.org/10.1016/j.omtm.2017.01.002
Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C. Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein. Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17. PMID: 28344996; PMCID: PMC5363313.
Copy Download .nbib Format: NLM
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Oncoimmunology

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 25949870
Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.

An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal...

Cite
Vacchelli E, Pol J, Bloy N, et al. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4(1):e985940doi: 10.4161/2162402X.2014.985940.
Vacchelli, E., Pol, J., Bloy, N., Eggermont, A., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology, 4(1), e985940. https://doi.org/10.4161/2162402X.2014.985940
Vacchelli, Erika, et al. "Trial watch: Tumor-targeting monoclonal antibodies for oncological indications." Oncoimmunology vol. 4,1 (2015): e985940. doi: https://doi.org/10.4161/2162402X.2014.985940
Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology. 2015 Feb 03;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan. PMID: 25949870; PMCID: PMC4368132.
Copy Download .nbib Format: NLM
Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6.

JIMD reports

Reid ES, Williams H, Stabej Ple Q, James C, Ocaka L, Bacchelli C, Footitt EJ, Boyd S, Cleary MA, Mills PB, Clayton PT.
PMID: 26446091
JIMD Rep. 2016;27:79-84. doi: 10.1007/8904_2015_460. Epub 2015 Oct 08.

There is increasing evidence that vitamin B6, given either as pyridoxine or pyridoxal 5'-phosphate, can sometimes result in improved seizure control in idiopathic epilepsy. Whole-exome sequencing was used to identify a de novo mutation (c.629G>A; p.Arg210His) in KCNQ2 in...

Cite
Reid ES, Williams H, Stabej Ple Q, et al. Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6. JIMD Rep. 2015;27:79-84doi: 10.1007/8904_2015_460.
Reid, E. S., Williams, H., Stabej, P. l. e. . Q., James, C., Ocaka, L., Bacchelli, C., Footitt, E. J., Boyd, S., Cleary, M. A., Mills, P. B., & Clayton, P. T. (2016). Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6. JIMD reports, 2779-84. https://doi.org/10.1007/8904_2015_460
Reid, Emma S, et al. "Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6." JIMD reports vol. 27 (2016): 79-84. doi: https://doi.org/10.1007/8904_2015_460
Reid ES, Williams H, Stabej Ple Q, James C, Ocaka L, Bacchelli C, Footitt EJ, Boyd S, Cleary MA, Mills PB, Clayton PT. Seizures Due to a KCNQ2 Mutation: Treatment with Vitamin B6. JIMD Rep. 2016;27:79-84. doi: 10.1007/8904_2015_460. Epub 2015 Oct 08. PMID: 26446091; PMCID: PMC5580730.
Copy Download .nbib Format: NLM
Cytogenetic and molecular characterization of a recombinant X chromosome in a family with a severe neurologic phenotype and macular degeneration.

Molecular cytogenetics

Magini P, Poscente M, Ferrari S, Vargiolu M, Bacchelli E, Graziano C, Wischmeijer A, Turchetti D, Malaspina E, Marchiani V, Cordelli DM, Franzoni E, Romeo G, Seri M.
PMID: 26236399
Mol Cytogenet. 2015 Aug 01;8:58. doi: 10.1186/s13039-015-0164-1. eCollection 2015.

BACKGROUND: Duplications of MECP2 gene in males cause a syndrome characterized by distinctive clinical features, including severe to profound mental retardation, infantile hypotonia, mild dysmorphic features, poor speech development, autistic features, seizures, progressive spasticity and recurrent infections. Patients with...

Cite
Magini P, Poscente M, Ferrari S, et al. Cytogenetic and molecular characterization of a recombinant X chromosome in a family with a severe neurologic phenotype and macular degeneration. Mol Cytogenet. 2015;8:58doi: 10.1186/s13039-015-0164-1.
Magini, P., Poscente, M., Ferrari, S., Vargiolu, M., Bacchelli, E., Graziano, C., Wischmeijer, A., Turchetti, D., Malaspina, E., Marchiani, V., Cordelli, D. M., Franzoni, E., Romeo, G., & Seri, M. (2015). Cytogenetic and molecular characterization of a recombinant X chromosome in a family with a severe neurologic phenotype and macular degeneration. Molecular cytogenetics, 858. https://doi.org/10.1186/s13039-015-0164-1
Magini, Pamela, et al. "Cytogenetic and molecular characterization of a recombinant X chromosome in a family with a severe neurologic phenotype and macular degeneration." Molecular cytogenetics vol. 8 (2015): 58. doi: https://doi.org/10.1186/s13039-015-0164-1
Magini P, Poscente M, Ferrari S, Vargiolu M, Bacchelli E, Graziano C, Wischmeijer A, Turchetti D, Malaspina E, Marchiani V, Cordelli DM, Franzoni E, Romeo G, Seri M. Cytogenetic and molecular characterization of a recombinant X chromosome in a family with a severe neurologic phenotype and macular degeneration. Mol Cytogenet. 2015 Aug 01;8:58. doi: 10.1186/s13039-015-0164-1. eCollection 2015. PMID: 26236399; PMCID: PMC4522089.
Copy Download .nbib Format: NLM
Common and rare variants of microRNA genes in autism spectrum disorders.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

Toma C, Torrico B, Hervás A, Salgado M, Rueda I, Valdés-Mas R, Buitelaar JK, Rommelse N, Franke B, Freitag C, Reif A, Pérez-Jurado LA, Battaglia A, Mazzone L, Bacchelli E, Puente XS, Cormand B.
PMID: 25903372
World J Biol Psychiatry. 2015 Sep;16(6):376-386. doi: 10.3109/15622975.2015.1029518. Epub 2015 Apr 23.

OBJECTIVES: MicroRNAs (miRNAs) are post-transcriptional regulators that have been shown to be involved in disease susceptibility. Here we explore the possible contribution of common and rare variants in miRNA genes in autism spectrum disorders (ASD).METHODS: A total of 350...

Cite
Toma C, Torrico B, Hervás A, et al. Common and rare variants of microRNA genes in autism spectrum disorders. World J Biol Psychiatry. 2015;16(6):376-386doi: 10.3109/15622975.2015.1029518.
Toma, C., Torrico, B., Hervás, A., Salgado, M., Rueda, I., Valdés-Mas, R., Buitelaar, J. K., Rommelse, N., Franke, B., Freitag, C., Reif, A., Pérez-Jurado, L. A., Battaglia, A., Mazzone, L., Bacchelli, E., Puente, X. S., & Cormand, B. (2015). Common and rare variants of microRNA genes in autism spectrum disorders. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 16(6), 376-386. https://doi.org/10.3109/15622975.2015.1029518
Toma, Claudio, et al. "Common and rare variants of microRNA genes in autism spectrum disorders." The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry vol. 16,6 (2015): 376-386. doi: https://doi.org/10.3109/15622975.2015.1029518
Toma C, Torrico B, Hervás A, Salgado M, Rueda I, Valdés-Mas R, Buitelaar JK, Rommelse N, Franke B, Freitag C, Reif A, Pérez-Jurado LA, Battaglia A, Mazzone L, Bacchelli E, Puente XS, Cormand B. Common and rare variants of microRNA genes in autism spectrum disorders. World J Biol Psychiatry. 2015 Sep;16(6):376-386. doi: 10.3109/15622975.2015.1029518. Epub 2015 Apr 23. PMID: 25903372.
Copy Download .nbib Format: NLM
[Hans Spitzy].

La Chirurgia degli organi di movimento

VACCHELLI S.
PMID: 13437393
Chir Organi Mov. 1957;44(1):68-9.

No abstract available.

Cite
VACCHELLI S. Hans Spitzy. [Hans Spitzy]. Chir Organi Mov. 1957;44(1):68-9
VACCHELLI, S. (1957). Hans Spitzy. [Hans Spitzy]. La Chirurgia degli organi di movimento, 44(1), 68-9.
VACCHELLI, S. "Hans Spitzy." [Hans Spitzy]. La Chirurgia degli organi di movimento vol. 44,1 (1957): 68-9.
VACCHELLI S. Hans Spitzy. [Hans Spitzy]. Chir Organi Mov. 1957;44(1):68-9. Italian. PMID: 13437393.
Copy Download .nbib Format: NLM
The reduction of food intake induced in mice by benzylamine and its derivatives.

Inflammopharmacology

Raimondi L, Banchelli G, Ghelardini C, Pirisino R.
PMID: 15035821
Inflammopharmacology. 2003;11(2):189-94. doi: 10.1163/156856003765764362.

Characterisation of the pharmacological profile of non-physiological amine oxidase substrates could help to identify the endogenous role of this class of enzymes. Previous studies have suggested that benzylamine, a common non-physiological substrate for monoamine and tissue-bound or soluble benzylamine...

Cite
Raimondi L, Banchelli G, Ghelardini C, et al. The reduction of food intake induced in mice by benzylamine and its derivatives. Inflammopharmacology. 2003;11(2):189-94doi: 10.1163/156856003765764362.
Raimondi, L., Banchelli, G., Ghelardini, C., & Pirisino, R. (2003). The reduction of food intake induced in mice by benzylamine and its derivatives. Inflammopharmacology, 11(2), 189-94. https://doi.org/10.1163/156856003765764362
Raimondi, L, et al. "The reduction of food intake induced in mice by benzylamine and its derivatives." Inflammopharmacology vol. 11,2 (2003): 189-94. doi: https://doi.org/10.1163/156856003765764362
Raimondi L, Banchelli G, Ghelardini C, Pirisino R. The reduction of food intake induced in mice by benzylamine and its derivatives. Inflammopharmacology. 2003;11(2):189-94. doi: 10.1163/156856003765764362. PMID: 15035821.
Copy Download .nbib Format: NLM
Hepatocyte transplantation: State of the art.

Hepatology research : the official journal of the Japan Society of Hepatology

Galvão FH, de Andrade Júnior DR, de Andrade DR, Martins BC, Marson AG, Bernard CV, Dos Santos SA, Bacchella T, Machado MC.
PMID: 17015036
Hepatol Res. 2006 Dec;36(4):237-47. doi: 10.1016/j.hepres.2006.08.008. Epub 2006 Oct 02.

Advances in biotechnology have allowed hepatocyte transplantation as a relevant proposition to treat liver disease. This procedure may change the crescent mortality in liver transplantation waiting lists due global organ shortage. Recent clinical trials have described promising results of...

Cite
Galvão FH, de Andrade Júnior DR, de Andrade DR, et al. Hepatocyte transplantation: State of the art. Hepatol Res. 2006;36(4):237-47doi: 10.1016/j.hepres.2006.08.008.
Galvão, F. H., de Andrade Júnior, D. R., de Andrade, D. R., Martins, B. C., Marson, A. G., Bernard, C. V., Dos Santos, S. A., Bacchella, T., & Machado, M. C. (2006). Hepatocyte transplantation: State of the art. Hepatology research : the official journal of the Japan Society of Hepatology, 36(4), 237-47. https://doi.org/10.1016/j.hepres.2006.08.008
Galvão, Flávio Henrique Ferreira, et al. "Hepatocyte transplantation: State of the art." Hepatology research : the official journal of the Japan Society of Hepatology vol. 36,4 (2006): 237-47. doi: https://doi.org/10.1016/j.hepres.2006.08.008
Galvão FH, de Andrade Júnior DR, de Andrade DR, Martins BC, Marson AG, Bernard CV, Dos Santos SA, Bacchella T, Machado MC. Hepatocyte transplantation: State of the art. Hepatol Res. 2006 Dec;36(4):237-47. doi: 10.1016/j.hepres.2006.08.008. Epub 2006 Oct 02. PMID: 17015036.
Copy Download .nbib Format: NLM
Current trends of anticancer immunochemotherapy.

Oncoimmunology

Vacchelli E, Prada N, Kepp O, Galluzzi L.
PMID: 23894726
Oncoimmunology. 2013 Jun 01;2(6):e25396. doi: 10.4161/onci.25396. Epub 2013 Jun 13.

No abstract available.

Cite
Vacchelli E, Prada N, Kepp O, et al. Current trends of anticancer immunochemotherapy. Oncoimmunology. 2013;2(6):e25396doi: 10.4161/onci.25396.
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013). Current trends of anticancer immunochemotherapy. Oncoimmunology, 2(6), e25396. https://doi.org/10.4161/onci.25396
Vacchelli, Erika, et al. "Current trends of anticancer immunochemotherapy." Oncoimmunology vol. 2,6 (2013): e25396. doi: https://doi.org/10.4161/onci.25396
Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology. 2013 Jun 01;2(6):e25396. doi: 10.4161/onci.25396. Epub 2013 Jun 13. PMID: 23894726; PMCID: PMC3716761.
Copy Download .nbib Format: NLM
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.

Oncoimmunology

Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, Kroemer G.
PMID: 23264921
Oncoimmunology. 2012 Dec 01;1(9):1640-1642. doi: 10.4161/onci.21684.

Retrospective clinical data indicate that cardiac glycosides (CGs), notably digoxin, prolong the survival of carcinoma patients treated with conventional chemotherapy. CGs are known to influence the immune response at multiple levels. In addition, recent results suggest that CGs trigger...

Cite
Kepp O, Menger L, Vacchelli E, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology. 2012;1(9):1640-1642doi: 10.4161/onci.21684.
Kepp, O., Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Sukkurwala, A. Q., Michaud, M., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2012). Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology, 1(9), 1640-1642. https://doi.org/10.4161/onci.21684
Kepp, Oliver, et al. "Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects." Oncoimmunology vol. 1,9 (2012): 1640-1642. doi: https://doi.org/10.4161/onci.21684
Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Sukkurwala AQ, Michaud M, Galluzzi L, Zitvogel L, Kroemer G. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology. 2012 Dec 01;1(9):1640-1642. doi: 10.4161/onci.21684. PMID: 23264921; PMCID: PMC3525630.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 185 entries